Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-255 in Relapsed/Refractory Hematological Malignancies
NCT04136756Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2019
- Primary completion
- Apr 2023
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of NKTR-255 in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Nektar Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 as a single agent at 6 months, Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 with daratumumab SC at 1 year and 4 more. Started Oct 2019; status: completed.
02
Drugs
NKTR-255
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04136756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136756.